Association of heart structure and function abnormalities with laboratory findings in patients with systemic lupus erythematosus

Lupus

Volumn 20, Issue 9, 2011, Pages 936-944

  Plazak, W ^a   Gryga, K ^a   Milewski, M ^a   Podolec, M ^a   Kostkiewicz, M ^a   Podolec, P ^a   Musial, J ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

autoimmune diseases; echocardiography; perfusion scintigraphy; SPECT; systemic lupus erythematosus

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C4; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HEART FUNCTION; HEART MUSCLE PERFUSION; HEART VALVE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTOLIC BLOOD PRESSURE; VALVULAR HEART DISEASE;

ADULT; AGED; ANTIBODIES, ANTICARDIOLIPIN; BETA 2-GLYCOPROTEIN I; C-REACTIVE PROTEIN; COMPLEMENT C3C; COMPLEMENT C4; ECHOCARDIOGRAPHY; FEMALE; HEART; HUMANS; HYPERTENSION; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MYOCARDIUM; PROGNOSIS; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 80052522672     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203311399607     Document Type: Article

References (36)

1. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006 ; 54: 2550-2557 (Pubitemid 44205016)
2. Pons-Estel GJ, Gonzales LA, Zhang J, et al. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multicenter US cohort. Rheumatology. 2009 ; 48: 817-822
3. Klocke FJ, Baird MG, Bateman TM, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Radionuclide Imaging). ACC/AHA Practice Guidelines; Circulation 2003; 108: 1404-1418 (Pubitemid 37174421)
4. Bessant R, Hingorani A, Patel L, et al. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford). 2004 ; 43: 924-929 (Pubitemid 38996970)
5. Bruce IN, Urowitz MB, Galdman DD, Ibanez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum. 2003 ; 48: 3159-3167 (Pubitemid 37409327)
6. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001 ; 44: 2331-2337 (Pubitemid 32977500)
7. Farzaneh-Far A, Roman MJ, Lockshin MD, et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006 ; 54: 3918-3925 (Pubitemid 44955895)
8. Doria A, Iaccarino L, Sarzi-Puttini P, et al. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005 ; 14: 683-686 (Pubitemid 41413291)
9. Jain D, Halushka MK. Cardiac pathology of systemic lupus erythematosus. J Clin Pathol. 2009 ; 62: 584-592
10. Amigo MC. The heart and APS. Clin Rev Allerg Immunol. 2007 ; 32: 178-183
11. Roldan CA. Valvular and coronary heart disease in systemic inflammatory diseases: systemic disorders in heart disease. Heart. 2008 ; 94: 1089-1101 (Pubitemid 352039899)
12. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Heamost. 2006 ; 4: 295-306
13. Smolen J, Weisman M Connective tissue disorders. Hochberg M Silman A Smolen J Weinblatt M Weisman M, ed. Rheumatology. Philadelphia: Mosby Elsevier, ; 2008: 1205-1485.
14. Smith EL, Shmerling RH. The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: strengths, weaknesses, and opportunities for improvement. Lupus. 1999 ; 8: 586-595 (Pubitemid 29520523)
15. Swadzba J, de Clerck LS, Stevens WJ, et al. Anticardiolipin antibodies, anti-β2-glycoprotein I, antiprothrombin antibodies and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. J Rheumatol. 1997 ; 24: 1710-1715 (Pubitemid 27394506)
16. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standarisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009 ; 7: 1737-1740
17. Permarheum SLEDAI Calculator, http://www.permarheum.org/SLEDAI.html (consulted) (accessed 15.02.2011)
18. Lin CC, Ding HJ, Chen YW, et al. Usefulness of technetium-99m sestamibi myocardial perfusion SPECT in detection of cardiovascular involvement in patients with systemic lupus erythematosus or systemic sclerosis. Int J Cardiol. 2003 ; 92: 157-161
19. Lin JJ, Hsu HB, Sun SS, et al. Single Photon Emission Computed Tomography of technetium-99m tetrofosmin myocardial perfusion imaging in patients with systemic lupus erythematosus-a preliminary report. Jpn Heart J. 2003 ; 44: 83-89
20. Cacciapuoti F, Galzerano D, Capogrosso P, et al. Impairment of left ventricular function in systemic lupus erythematosus evaluated by measuring myocardial performance index with tissue Doppler echocardiography. Echocardiography. 2005 ; 22: 315-319 (Pubitemid 40559531)
21. Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC Diseases of connective tissue. Braun-Falco O, ed. Dermatology, Berlin: Springer-Verlag, ; 2000: 789-789.
22. Kovacs G, Maier R, Aberer E, et al. Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma. Am J Respir Crit Care Med. 2009 ; 180: 881-886
23. Vanzetto G, Ormezzano O, Fagret D, Comet M, Denis B, Machecourt J. Long term additive prognostic value of thalium-201 myocardial perfusion imaging over clinical and exercise stress test in low to intermediate risk patients: study in 1137 patients with 6-year follow-up. Circulation. 1999 ; 100: 1521-1527 (Pubitemid 29461464)
24. Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation. 1998 ; 97: 535-543 (Pubitemid 28090682)
25. Wiik AS, Fritzler MJ Laboratory tests in rheumatic disorders. Hochberg M Silman A Smolen J Weinblatt M Weisman M, ed. Philadelphia, PA: Mosby Elsevier, ; 2008: 219-232.
26. Cefle A, Inanc M, Sayarlioglu M, et al. Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int 2009; December 11, Epub ahead of print
27. Hasegawa EM, Caleiro MT, Fuller R, Carvalho JF. The frequency of anti-beta2-glycoprotein I antibodies is low and these antibodies are associated with pulmonary hypertension in mixed connective tissue disease. Lupus. 2009 ; 18: 618-621
28. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res. 2004 ; 114: 593-595 (Pubitemid 39422596)
29. Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J. 2002 ; 144: 233-238 (Pubitemid 34879645)
30. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 ; 342: 836-843 (Pubitemid 30165206)
31. Kao AH, Sabatine JM, Manzi S. Update on vascular disease in systemic lupus erythematosus. Curr Opin Rheum. 2003 ; 15: 519-527 (Pubitemid 37041387)
32. Tomita M, Dragoman M, Worcester H, Conran P, Santoro TJ. Proinflammatory cytokine genes are constitutively overexpressed in the heart in experimental systemic lupus erythematosus: a brief communication. Exp Biol Med. 2004 ; 229: 971-976 (Pubitemid 39539384)
33. Silbiger JJ. The cardiac manifestations of antiphospholipid syndrome and their echocardiographic recognition. J Am Soc Echocardiogr. 2009 ; 22: 1100-1108
34. Haas C. Pulmonary hypertension associated with systemic lupus erythematosus. Bull Acad Natl Med. 2004 ; 188: 985-997 (Pubitemid 40081463)
35. Giron-Gonzales JA, Garcia del Rio E, Rodriguez C, Rodriguez-Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004 ; 31: 1560-1567 (Pubitemid 39006638)
36. Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med. 2000 ; 160: 2042-2048 (Pubitemid 30437588)